Illumina Plans to Acquire SomaLogic for Up to $425 Million

Illumina Plans to Acquire SomaLogic for Up to $425 Million

Illumina, a leading player in the genomic sequencing market, has announced its acquisition of SomaLogic for $350 million in cash, plus up to $75 million in near-term performance-based milestones and royalties. This strategic move aims to accelerate and expand Illumina's proteomics business, furthering its multiomics strategy revealed in 2024.

Based in Boulder, Colorado, SomaLogic is a pioneer in data-driven proteomics technology, specialising in aptamer-based proteomics and protein biomarker discovery. With a global footprint and CLIA- and CAP-certified lab facilities, SomaLogic's technology offers high sensitivity, scalability, and technical reproducibility, measuring thousands of protein markers in a single experiment.

The acquisition builds upon a co-development partnership between Illumina and SomaLogic, established since December 2021, to integrate SomaLogic’s SomaScan® Proteomics Assay onto Illumina’s high-throughput next-generation sequencing (NGS) platforms. Illumina’s Protein Prep, currently with nearly 40 early-access customers, is set to become broadly available in Q3 2025.

The combination of SomaLogic’s proteomics offerings with Illumina’s scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics platform is expected to accelerate proteomics technology development, reduce time and cost of research, and enhance capabilities for advanced biomarker discovery and disease profiling.

Strategically, the acquisition strengthens Illumina’s presence in the expanding proteomics market, complementing its existing genomic sequencing leadership, and supports its vision of integrated multiomics—leveraging genomics, proteomics, and other omics technologies to provide deeper biological insights and support personalized medicine and early disease detection.

Standard BioTools, which acquired SomaLogic and its SomaScan technology 18 months ago, will retain certain reagent commercialization rights on SOMAmer kits. Illumina remains committed to maintaining its existing proteomics partnerships and supporting a variety of multiomics solutions.

The acquisition is expected to enhance Illumina’s multiomics product offerings by combining genomics and proteomics on a single scalable platform. It will advance Illumina’s technology roadmap to enable faster, more comprehensive biomarker discovery and disease profiling. The deal also aims to expand Illumina’s market reach and capabilities in proteomics and biosensing applications critical to early disease detection and personalized health care.

Jacob Thaysen, CEO of Illumina, stated that the combination with SomaLogic increases their ability to serve customers and accelerate their technology roadmap towards advanced biomarker discovery and disease profiling. Standard BioTools expects the adjusted earnings before interest, tax, depreciation, and amortization to achieve break-even after the transaction. The acquisition is also expected to simplify Standard BioTools' operating structure.

SomaLogic's Boulder, Colorado facilities, including a lab, office, and manufacturing space, will be part of the purchase. Illumina stated that the acquisition of SomaLogic will advance their multiomics strategy and strengthen the value of their NovaSeq X products.

[1] Illumina press release, 2025 [2] SomaLogic press release, 2025 [3] Bio-IT World, 2025 [4] GenomeWeb, 2025 [5] Nature, 2025

1. The $350 million acquisition of SomaLogic, a pioneer in data-driven proteomics technology, by Illumina is set to advance Illumina's proteomics business, strengthening their multiomics strategy in the expanding proteomics market.
2. The combination of SomaLogic's proteomics offerings with Illumina's scalable next-generation sequencing (NGS) ecosystem, analytical tools, and multiomics platform is expected to accelerate proteomics technology development, reduce research time and cost, and enhance capabilities for advanced biomarker discovery and disease profiling.
3. Illumina's CEO, Jacob Thaysen, stated that the acquisition of SomaLogic will increase their ability to serve customers and accelerate their technology roadmap towards advanced biomarker discovery and disease profiling.
4. The acquisition of SomaLogic's facilities in Boulder, Colorado, including a lab, office, and manufacturing space, will contribute to Illumina's novel multiomics strategy and strengthen the value of their NovaSeq X products.
5. News outlets such as Bio-IT World, GenomeWeb, Nature, and the press releases from both Illumina and SomaLogic have reported on the strategic acquisition, highlighting its potential to expand Illumina's market reach and capabilities in proteomics and biosensing applications crucial for early disease detection and personalized health care.

Read also: